{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T05:56:48Z","timestamp":1774418208183,"version":"3.50.1"},"reference-count":133,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-025-04096-5","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T14:58:38Z","timestamp":1761577118000},"page":"1101-1118","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["RASSF1A and its epigenetic dysregulation in genitourinary cancer: a current update"],"prefix":"10.1007","volume":"28","author":[{"given":"Sandeep","family":"Appunni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivek","family":"Anand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madhuram","family":"Khandelwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nidhi","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muni","family":"Rubens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2735-1321","authenticated-orcid":false,"given":"Alpana","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"issue":"9","key":"4096_CR1","doi-asserted-by":"publisher","first-page":"3497","DOI":"10.1158\/0008-5472.CAN-04-4088","volume":"65","author":"A Agathanggelou","year":"2005","unstructured":"Agathanggelou A, Cooper WN, Latif F. Role of the ras-association domain family 1 tumor suppressor gene in human cancers. Cancer Res. 2005;65(9):3497\u2013508.","journal-title":"Cancer Res"},{"key":"4096_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2025.167977","author":"MO Iqbal","year":"2025","unstructured":"Iqbal MO, Wang Q, Khan IA, Gu Y, Wu X, Chen J. Ras association domain family member 1 (RASSF1): molecular characteristics, clinical relevance and therapeutic interventions in cancer. Biochim Biophys Acta (BBA)-Mol Basis Dis. 2025. https:\/\/doi.org\/10.1016\/j.bbadis.2025.167977.","journal-title":"Biochim Biophys Acta (BBA)-Mol Basis Dis"},{"issue":"1","key":"4096_CR3","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.bbcan.2007.06.003","volume":"1776","author":"L van der Weyden","year":"2007","unstructured":"van der Weyden L, Adams DJ. The Ras-association domain family (RASSF) members and their role in human tumourigenesis. Biochim Biophys Acta (BBA)-Rev Cancer. 2007;1776(1):58\u201385.","journal-title":"Biochim Biophys Acta (BBA)-Rev Cancer"},{"issue":"18","key":"4096_CR4","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1242\/jcs.010389","volume":"120","author":"H Donninger","year":"2007","unstructured":"Donninger H, Vos MD, Clark GJ. The RASSF1A tumor suppressor. J Cell Sci. 2007;120(18):3163\u201372.","journal-title":"J Cell Sci"},{"key":"4096_CR5","doi-asserted-by":"publisher","DOI":"10.4103\/1477-3163.93000","volume":"11","author":"KS Amin","year":"2012","unstructured":"Amin KS, Banerjee PP. The cellular functions of RASSF1A and its inactivation in prostate cancer. J Carcinog. 2012;11:3.","journal-title":"J Carcinog"},{"key":"4096_CR6","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.cca.2020.01.014","volume":"504","author":"Y Bin","year":"2020","unstructured":"Bin Y, Ding Y, Xiao W, Liao A. RASSF1A: a promising target for the diagnosis and treatment of cancer. Clin Chim Acta. 2020;504:98\u2013108.","journal-title":"Clin Chim Acta"},{"issue":"12","key":"4096_CR7","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1038\/s41419-019-2169-x","volume":"10","author":"F Dubois","year":"2019","unstructured":"Dubois F, Bergot E, Zalcman G, Levallet G. RASSF1A, puppeteer of cellular homeostasis, fights tumorigenesis, and metastasis\u2014an updated review. Cell Death Dis. 2019;10(12):928.","journal-title":"Cell Death Dis"},{"key":"4096_CR8","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3389\/fonc.2011.00032","volume":"1","author":"RM Bukowski","year":"2011","unstructured":"Bukowski RM. Genitourinary oncology: current status and future challenges. Front Oncol. 2011;1:32.","journal-title":"Front Oncol"},{"key":"4096_CR9","volume-title":"StatPearls [Internet]","author":"S Libretti","year":"2023","unstructured":"Libretti S, Aeddula NR. Embryology, genitourinary. In: StatPearls [Internet]. StatPearls Publishing; 2023."},{"key":"4096_CR10","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/B978-0-12-410396-2.00036-0","volume-title":"Translational regenerative medicine","author":"M Abolbashari","year":"2015","unstructured":"Abolbashari M, Atala A, Yoo JJ. Genitourinary system. In: Translational regenerative medicine. Elsevier; 2015. p. 495\u2013505."},{"key":"4096_CR11","volume-title":"Seminars in oncology","author":"D Raghavan","year":"2004","unstructured":"Raghavan D, Skinner E. Genitourinary cancer in the elderly. In: Seminars in oncology. Elsevier; 2004."},{"issue":"1","key":"4096_CR12","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s12957-025-03849-4","volume":"23","author":"X Su","year":"2025","unstructured":"Su X, Chen F, Shi Z, Tao Y, Han X, Xue L. Global insight of early-onset genitourinary cancers in adolescents and adults from 1990 to 2021: temporal trends and health inequalities analyses. World J Surg Oncol. 2025;23(1):208.","journal-title":"World J Surg Oncol"},{"issue":"2","key":"4096_CR13","doi-asserted-by":"publisher","first-page":"63","DOI":"10.14740\/wjon1191","volume":"10","author":"P Rawla","year":"2019","unstructured":"Rawla P. Epidemiology of prostate cancer. World J Oncol. 2019;10(2):63.","journal-title":"World J Oncol"},{"issue":"6","key":"4096_CR14","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.3390\/cancers15061856","volume":"15","author":"D Thompson","year":"2023","unstructured":"Thompson D, Lawrentschuk N, Bolton D. New approaches to targeting epigenetic regulation in bladder cancer. Cancers. 2023;15(6):1856.","journal-title":"Cancers"},{"issue":"6","key":"4096_CR15","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1038\/s43018-024-00777-2","volume":"5","author":"NW Mabe","year":"2024","unstructured":"Mabe NW, Perry JA, Malone CF, Stegmaier K. Pharmacological targeting of the cancer epigenome. Nat Cancer. 2024;5(6):844\u201365.","journal-title":"Nat Cancer"},{"issue":"13","key":"4096_CR16","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2018100532","volume":"38","author":"D Pankova","year":"2019","unstructured":"Pankova D, Jiang Y, Chatzifrangkeskou M, Vendrell I, Buzzelli J, Ryan A, et al. RASSF 1A controls tissue stiffness and cancer stem-like cells in lung adenocarcinoma. EMBO J. 2019;38(13):e100532.","journal-title":"EMBO J"},{"issue":"10","key":"4096_CR17","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.4161\/cbt.4.10.2023","volume":"4","author":"Z-G Pan","year":"2005","unstructured":"Pan Z-G, Kashuba VI, Liu X-Q, Shao J-Y, Zhang R-H, Jiang J-H, et al. High frequency somatic mutations in RASSF1A in nasopharyngeal carcinoma. Cancer Biol Ther. 2005;4(10):1116\u201322.","journal-title":"Cancer Biol Ther"},{"issue":"11","key":"4096_CR18","doi-asserted-by":"publisher","first-page":"5660","DOI":"10.3390\/ijms25115660","volume":"25","author":"P Koukourikis","year":"2024","unstructured":"Koukourikis P, Papaioannou M, Pervana S, Apostolidis A. Exploring the DNA methylation profile of genes associated with bladder cancer in bladder tissue of patients with neurogenic lower urinary tract dysfunction. Int J Mol Sci. 2024;25(11):5660.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4096_CR19","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3390\/cancers12010229","volume":"12","author":"L Garc\u00eda-Guti\u00e9rrez","year":"2020","unstructured":"Garc\u00eda-Guti\u00e9rrez L, McKenna S, Kolch W, Matallanas D. RASSF1A tumour suppressor: target the network for effective cancer therapy. Cancers. 2020;12(1):229.","journal-title":"Cancers"},{"issue":"3","key":"4096_CR20","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/bjc.2015.221","volume":"113","author":"A Grawenda","year":"2015","unstructured":"Grawenda A, O\u2019neill E. Clinical utility of RASSF1A methylation in human malignancies. Br J Cancer. 2015;113(3):372\u201381.","journal-title":"Br J Cancer"},{"issue":"6","key":"4096_CR21","doi-asserted-by":"publisher","first-page":"2878","DOI":"10.3892\/or.2013.2752","volume":"30","author":"R Fiolka","year":"2013","unstructured":"Fiolka R, Zubor P, Janusicova V, Visnovsky J, Mendelova A, Kajo K, et al. Promoter hypermethylation of the tumor-suppressor genes RASSF1A, GSTP1 and CDH1 in endometrial cancer. Oncol Rep. 2013;30(6):2878\u201386.","journal-title":"Oncol Rep"},{"issue":"1","key":"4096_CR22","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1080\/09674845.2019.1694123","volume":"77","author":"M El-Bendary","year":"2020","unstructured":"El-Bendary M, Nour D, Arafa M, Neamatallah M. Methylation of tumour suppressor genes RUNX3, RASSF1A and E-cadherin in HCV-related liver cirrhosis and hepatocellular carcinoma. Br J Biomed Sci. 2020;77(1):35\u201340.","journal-title":"Br J Biomed Sci"},{"issue":"6","key":"4096_CR23","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1155\/2009\/416923","volume":"31","author":"G Sharma","year":"2009","unstructured":"Sharma G, Mirza S, Yang Y-H, Parshad R, Hazrah P, Datta Gupta S, et al. Prognostic relevance of promoter hypermethylation of multiple genes in breast cancer patients. Anal Cell Pathol. 2009;31(6):487\u2013500.","journal-title":"Anal Cell Pathol"},{"issue":"3","key":"4096_CR24","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1097\/01.sla.0000086659.49569.9e","volume":"238","author":"MG House","year":"2003","unstructured":"House MG, Herman JG, Guo MZ, Hooker CM, Schulick RD, Lillemoe KD, et al. Aberrant hypermethylation of tumor suppressor genes in pancreatic endocrine neoplasms. Ann Surg. 2003;238(3):423.","journal-title":"Ann Surg"},{"key":"4096_CR25","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000009971","author":"G Wen","year":"2018","unstructured":"Wen G, Wang H, Zhong Z. Associations of RASSF1A, RAR\u03b2, and CDH1 promoter hypermethylation with oral cancer risk: a PRISMA-compliant meta-analysis. Medicine (Baltimore). 2018. https:\/\/doi.org\/10.1097\/MD.0000000000009971.","journal-title":"Medicine (Baltimore)"},{"key":"4096_CR26","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000014588","author":"L-y Feng","year":"2019","unstructured":"Feng L-y, Chen C-x, Li L. Hypermethylation of tumor suppressor genes is a risk factor for poor prognosis in ovarian cancer: a meta-analysis. Medicine. 2019. https:\/\/doi.org\/10.1097\/MD.0000000000014588.","journal-title":"Medicine"},{"issue":"6","key":"4096_CR27","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1007\/s00432-020-03188-9","volume":"146","author":"N Li","year":"2020","unstructured":"Li N, Zeng Y, Huang J. Signaling pathways and clinical application of RASSF1A and SHOX2 in lung cancer. J Cancer Res Clin Oncol. 2020;146(6):1379\u201393.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"9","key":"4096_CR28","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1159\/000534275","volume":"102","author":"B Xie","year":"2024","unstructured":"Xie B, Dong W, He F, Peng F, Zhang H, Wang W. The combination of SHOX2 and RASSF1A DNA methylation had a diagnostic value in pulmonary nodules and early lung cancer. Oncology. 2024;102(9):759\u201374.","journal-title":"Oncology"},{"key":"4096_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e34028","author":"Y Shan","year":"2024","unstructured":"Shan Y, Teng Y, Guan C, Mao Z, Lu C, Ding W, et al. Combined ultrasound endoscopy-guided fine-needle aspiration with DNA methylation of SHOX2 and RASSF1A genes to enhance the auxiliary diagnostic precision of pancreatic cancer. Heliyon. 2024. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e34028.","journal-title":"Heliyon"},{"issue":"5","key":"4096_CR30","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1159\/000538673","volume":"89","author":"C Chen","year":"2024","unstructured":"Chen C, Zhu Y, Zhang H, Xiao L. Prognostic effects of RASSF1A, BRCA1, APC, and p16 promoter methylation in ovarian cancer: a meta-analysis. Gynecol Obstet Invest. 2024;89(5):363\u201375.","journal-title":"Gynecol Obstet Invest"},{"key":"4096_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e33304","author":"Y Bai","year":"2024","unstructured":"Bai Y, Wang Y, Qin J, Wang T, Zhou X, Ma Z, et al. Systematic pan-cancer analysis identified RASSF1 as an immunological and prognostic biomarker and validated in lung cancer. Heliyon. 2024. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e33304.","journal-title":"Heliyon"},{"key":"4096_CR32","doi-asserted-by":"publisher","DOI":"10.4103\/1477-3163.93000","author":"KS Amin","year":"2012","unstructured":"Amin KS, Banerjee PP. The cellular functions of RASSF1A and its inactivation in prostate cancer. J Carcinog. 2012. https:\/\/doi.org\/10.4103\/1477-3163.93000.","journal-title":"J Carcinog"},{"issue":"24","key":"4096_CR33","doi-asserted-by":"publisher","first-page":"6214","DOI":"10.3390\/cancers13246214","volume":"13","author":"Y Xiao","year":"2021","unstructured":"Xiao Y, Dong J. The hippo signaling pathway in cancer: a cell cycle perspective. Cancers. 2021;13(24):6214.","journal-title":"Cancers"},{"issue":"7","key":"4096_CR34","doi-asserted-by":"publisher","first-page":"959","DOI":"10.3390\/cancers11070959","volume":"11","author":"G Malpeli","year":"2019","unstructured":"Malpeli G, Innamorati G, Decimo I, Bencivenga M, Nwabo Kamdje AH, Perris R, et al. Methylation dynamics of RASSF1A and its impact on cancer. Cancers. 2019;11(7):959.","journal-title":"Cancers"},{"issue":"1","key":"4096_CR35","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s11010-019-03648-y","volume":"464","author":"M Khandelwal","year":"2020","unstructured":"Khandelwal M, Anand V, Appunni S, Seth A, Singh P, Mathur S, et al. RASSF1A\u2013Hippo pathway link in patients with urothelial carcinoma of bladder: plausible therapeutic target. Mol Cell Biochem. 2020;464(1):51\u201363.","journal-title":"Mol Cell Biochem"},{"issue":"1","key":"4096_CR36","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s11010-018-3278-z","volume":"446","author":"M Khandelwal","year":"2018","unstructured":"Khandelwal M, Anand V, Appunni S, Seth A, Singh P, Mathur S, et al. Decitabine augments cytotoxicity of cisplatin and doxorubicin to bladder cancer cells by activating hippo pathway through RASSF1A. Mol Cell Biochem. 2018;446(1):105\u201314.","journal-title":"Mol Cell Biochem"},{"issue":"51","key":"4096_CR37","doi-asserted-by":"publisher","first-page":"88437","DOI":"10.18632\/oncotarget.18177","volume":"8","author":"AP Jim\u00e9nez","year":"2017","unstructured":"Jim\u00e9nez AP, Traum A, Boettger T, Hackstein H, Richter AM, Dammann RH. The tumor suppressor RASSF1A induces the YAP1 target gene ANKRD1 that is epigenetically inactivated in human cancers and inhibits tumor growth. Oncotarget. 2017;8(51):88437.","journal-title":"Oncotarget"},{"issue":"9","key":"4096_CR38","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.3390\/cancers12092689","volume":"12","author":"S Ro\u00dfwag","year":"2020","unstructured":"Ro\u00dfwag S, Thiede G, Sleeman JP, Thaler S. RASSF1A suppresses estrogen-dependent breast cancer cell growth through inhibition of the yes-associated protein 1 (YAP1), inhibition of the forkhead box protein M1 (FOXM1), and activation of forkhead box transcription factor 3A (FOXO3A). Cancers. 2020;12(9):2689.","journal-title":"Cancers"},{"issue":"11","key":"4096_CR39","doi-asserted-by":"publisher","first-page":"2868","DOI":"10.3390\/cells10112868","volume":"10","author":"S Ro\u00dfwag","year":"2021","unstructured":"Ro\u00dfwag S, Sleeman JP, Thaler S. RASSF1A-mediated suppression of estrogen receptor alpha (ER\u03b1)-driven breast cancer cell growth depends on the hippo-kinases LATS1 and 2. Cells. 2021;10(11):2868.","journal-title":"Cells"},{"issue":"22","key":"4096_CR40","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.2217\/epi-2023-0306","volume":"15","author":"A Gao","year":"2023","unstructured":"Gao A, Bai P, Zhang M, Yao Y, Herman JG, Guo M. RASSF1A promotes ATM signaling and RASSF1A methylation is a synthetic lethal marker for ATR inhibitors. Epigenomics. 2023;15(22):1205\u201320.","journal-title":"Epigenomics"},{"issue":"5","key":"4096_CR41","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1158\/0008-5472.CAN-05-2951","volume":"66","author":"HJ Oh","year":"2006","unstructured":"Oh HJ, Lee K-K, Song SJ, Jin MS, Song MS, Lee JH, et al. Role of the tumor suppressor RASSF1A in Mst1-mediated apoptosis. Cancer Res. 2006;66(5):2562\u20139.","journal-title":"Cancer Res"},{"issue":"50","key":"4096_CR42","doi-asserted-by":"publisher","first-page":"8125","DOI":"10.1038\/sj.onc.1206984","volume":"22","author":"L Liu","year":"2003","unstructured":"Liu L, Tommasi S, Lee D-H, Dammann R, Pfeifer GP. Control of microtubule stability by the RASSF1A tumor suppressor. Oncogene. 2003;22(50):8125\u201336.","journal-title":"Oncogene"},{"issue":"6","key":"4096_CR43","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1091\/mbc.e13-07-0374","volume":"25","author":"C Arnette","year":"2014","unstructured":"Arnette C, Efimova N, Zhu X, Clark GJ, Kaverina I. Microtubule segment stabilization by RASSF1A is required for proper microtubule dynamics and Golgi integrity. Mol Biol Cell. 2014;25(6):800\u201310.","journal-title":"Mol Biol Cell"},{"issue":"12","key":"4096_CR44","doi-asserted-by":"publisher","first-page":"4112","DOI":"10.1158\/0008-5472.CAN-04-0267","volume":"64","author":"A Dallol","year":"2004","unstructured":"Dallol A, Agathanggelou A, Fenton SL, Ahmed-Choudhury J, Hesson L, Vos MD, et al. RASSF1A interacts with microtubule-associated proteins and modulates microtubule dynamics. Cancer Res. 2004;64(12):4112\u20136.","journal-title":"Cancer Res"},{"issue":"6","key":"4096_CR45","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1002\/cncr.24113","volume":"115","author":"YM Whang","year":"2009","unstructured":"Whang YM, Park KH, Jung HY, Jo UH, Kim YH. Microtubule-damaging agents enhance RASSF1A-induced cell death in lung cancer cell lines. Cancer. 2009;115(6):1253\u201366.","journal-title":"Cancer"},{"issue":"4","key":"4096_CR46","doi-asserted-by":"publisher","first-page":"437","DOI":"10.3390\/jmp5040029","volume":"5","author":"I Klabukov","year":"2024","unstructured":"Klabukov I, Smirnova A, Yakimova A, Kabakov AE, Atiakshin D, Petrenko D, et al. Oncomatrix: molecular composition and biomechanical properties of the extracellular matrix in human tumors. J Mol Pathol. 2024;5(4):437\u201353.","journal-title":"J Mol Pathol"},{"issue":"19","key":"4096_CR47","doi-asserted-by":"publisher","first-page":"4754","DOI":"10.3390\/cancers13194754","volume":"13","author":"M Amer","year":"2021","unstructured":"Amer M, Shi L, Wolfenson H. The \u2018yin and yang\u2019of cancer cell growth and mechanosensing. Cancers. 2021;13(19):4754.","journal-title":"Cancers"},{"issue":"5","key":"4096_CR48","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41419-024-06697-4","volume":"15","author":"Z Mai","year":"2024","unstructured":"Mai Z, Lin Y, Lin P, Zhao X, Cui L. Modulating extracellular matrix stiffness: a strategic approach to boost cancer immunotherapy. Cell Death Dis. 2024;15(5):307.","journal-title":"Cell Death Dis"},{"issue":"7350","key":"4096_CR49","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/nature10137","volume":"474","author":"S Dupont","year":"2011","unstructured":"Dupont S, Morsut L, Aragona M, Enzo E, Giulitti S, Cordenonsi M, et al. Role of YAP\/TAZ in mechanotransduction. Nature. 2011;474(7350):179\u201383.","journal-title":"Nature"},{"issue":"16","key":"4096_CR50","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.1016\/j.febslet.2014.04.012","volume":"588","author":"BC Low","year":"2014","unstructured":"Low BC, Pan CQ, Shivashankar G, Bershadsky A, Sudol M, Sheetz M. YAP\/TAZ as mechanosensors and mechanotransducers in regulating organ size and tumor growth. FEBS Lett. 2014;588(16):2663\u201370.","journal-title":"FEBS Lett"},{"issue":"6","key":"4096_CR51","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1158\/0008-5472.CAN-15-1008","volume":"76","author":"F Dubois","year":"2016","unstructured":"Dubois F, Keller M, Calvayrac O, Soncin F, Hoa L, Hergovich A, et al. RASSF1A suppresses the invasion and metastatic potential of human non\u2013small cell lung cancer cells by inhibiting YAP activation through the GEF-H1\/RhoB pathway. Cancer Res. 2016;76(6):1627\u201340.","journal-title":"Cancer Res"},{"issue":"7","key":"4096_CR52","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1158\/0008-5472.CAN-15-1752","volume":"76","author":"M-G Lee","year":"2016","unstructured":"Lee M-G, Jeong S-I, Ko K-P, Park S-K, Ryu B-K, Kim I-Y, et al. RASSF1A directly antagonizes RhoA activity through the assembly of a Smurf1-mediated destruction complex to suppress tumorigenesis. Can Res. 2016;76(7):1847\u201359.","journal-title":"Can Res"},{"issue":"13","key":"4096_CR53","doi-asserted-by":"publisher","first-page":"3251","DOI":"10.3390\/cancers13133251","volume":"13","author":"G Reye","year":"2021","unstructured":"Reye G, Huang X, Britt KL, Meinert C, Blick T, Xu Y, et al. RASSF1A suppression as a potential regulator of mechano-pathobiology associated with mammographic density in BRCA mutation carriers. Cancers. 2021;13(13):3251.","journal-title":"Cancers"},{"issue":"3","key":"4096_CR54","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"4096_CR55","doi-asserted-by":"publisher","DOI":"10.1186\/1617-9625-2-3-141","author":"JT Quirk","year":"2004","unstructured":"Quirk JT, Li Q, Natarajan N, Mettlin CJ, Cummings KM. Cigarette smoking and the risk of bladder cancer in men and women. Tob Induc Dis. 2004. https:\/\/doi.org\/10.1186\/1617-9625-2-3-141.","journal-title":"Tob Induc Dis"},{"issue":"3","key":"4096_CR56","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1093\/ije\/dyv195","volume":"45","author":"S Koutros","year":"2016","unstructured":"Koutros S, Silverman DT, Alavanja MC, Andreotti G, Lerro CC, Heltshe S, et al. Occupational exposure to pesticides and bladder cancer risk. Int J Epidemiol. 2016;45(3):792\u2013805.","journal-title":"Int J Epidemiol"},{"issue":"1","key":"4096_CR57","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1097\/EDE.0000000000001112","volume":"31","author":"KH Barry","year":"2020","unstructured":"Barry KH, Jones RR, Cantor KP, Freeman LEB, Wheeler DC, Baris D, et al. Ingested nitrate and nitrite and bladder cancer in northern New England. Epidemiology. 2020;31(1):136\u201344.","journal-title":"Epidemiology"},{"key":"4096_CR58","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s40291-013-0023-x","volume":"17","author":"S Goodison","year":"2013","unstructured":"Goodison S, Rosser CJ, Urquidi V. Bladder cancer detection and monitoring: assessment of urine-and blood-based marker tests. Mol Diagn Ther. 2013;17:71\u201384.","journal-title":"Mol Diagn Ther"},{"issue":"5","key":"4096_CR59","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1097\/MOU.0b013e32830b86d1","volume":"18","author":"M Lodde","year":"2008","unstructured":"Lodde M, Fradet Y. The detection of genetic markers of bladder cancer in urine and serum. Curr Opin Urol. 2008;18(5):499\u2013503.","journal-title":"Curr Opin Urol"},{"key":"4096_CR60","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.suronc.2019.05.009","volume":"30","author":"Y Bao","year":"2019","unstructured":"Bao Y, Liu X, Liu Y, Wang S, Wu B. Ras-association domain family 1 (RASSF1A) gene regulates progression, migration and invasion of bladder cancer. Surg Oncol. 2019;30:63\u201371.","journal-title":"Surg Oncol"},{"key":"4096_CR61","volume-title":"Urologic oncology: seminars and original investigations","author":"H-H Lin","year":"2012","unstructured":"Lin H-H, Ke H-L, Wu W-J, Lee Y-H, Chang L-L. Hypermethylation of E-cadherin, p16, p14, and RASSF1A genes in pathologically normal urothelium predict bladder recurrence of bladder cancer after transurethral resection. In: Urologic oncology: seminars and original investigations. Elsevier; 2012."},{"key":"4096_CR62","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000006097","author":"L Zhan","year":"2017","unstructured":"Zhan L, Zhang B, Tan Y, Yang C, Huang C, Wu Q, et al. Quantitative assessment of the relationship between RASSF1A gene promoter methylation and bladder cancer (PRISMA). Medicine. 2017. https:\/\/doi.org\/10.1097\/MD.0000000000006097.","journal-title":"Medicine"},{"issue":"11","key":"4096_CR63","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0048300","volume":"7","author":"T Gao","year":"2012","unstructured":"Gao T, Wang S, He B, Pan Y, Song G, Gu L, et al. The association of RAS association domain family protein1A (RASSF1A) methylation states and bladder cancer risk: a systematic review and meta-analysis. PLoS ONE. 2012;7(11):e48300.","journal-title":"PLoS ONE"},{"issue":"1","key":"4096_CR64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.69709\/GenomC.2025.145625","volume":"2","author":"M Hussein","year":"2025","unstructured":"Hussein M. Epigenetic insights into bladder cancer: the role of urine DNA methylation assays: mini review. GenoMed Connect. 2025;2(1):1\u201310.","journal-title":"GenoMed Connect"},{"key":"4096_CR65","volume-title":"Urologic oncology: seminars and original investigations","author":"H-H Lin","year":"2010","unstructured":"Lin H-H, Ke H-L, Huang S-P, Wu W-J, Chen Y-K, Chang L-L. Increase sensitivity in detecting superficial, low grade bladder cancer by combination analysis of hypermethylation of E-cadherin, p16, p14, RASSF1A genes in urine. In: Urologic oncology: seminars and original investigations. Elsevier; 2010."},{"key":"4096_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1755-8794-4-45","volume":"4","author":"P-C Chen","year":"2011","unstructured":"Chen P-C, Tsai M-H, Yip SK, Jou Y-C, Ng C-F, Chen Y, et al. Distinct DNA methylation epigenotypes in bladder cancer from different Chinese sub-populations and its implication in cancer detection using voided urine. BMC Med Genomics. 2011;4:1\u201311.","journal-title":"BMC Med Genomics"},{"issue":"8","key":"4096_CR67","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0200906","volume":"13","author":"J Bosschieter","year":"2018","unstructured":"Bosschieter J, Bach S, Bijnsdorp I, Segerink L, Rurup WF, Van Splunter A, et al. A protocol for urine collection and storage prior to DNA methylation analysis. PLoS ONE. 2018;13(8):e0200906.","journal-title":"PLoS ONE"},{"key":"4096_CR68","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/6328503","author":"M Shan","year":"2019","unstructured":"Shan M, Zhang L, Liu Y, Gao C, Kang W, Yang W, et al. DNA methylation profiles and their diagnostic utility in BC. Dis Markers. 2019. https:\/\/doi.org\/10.1155\/2019\/6328503.","journal-title":"Dis Markers"},{"issue":"1","key":"4096_CR69","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3233\/CBM-160673","volume":"18","author":"M Pietrusi\u0144ski","year":"2017","unstructured":"Pietrusi\u0144ski M, K\u0229pczy\u0144ski \u023d, J\u0229drzejczyk A, Borkowska E, Traczyk-Borszy\u0144ska M, Constantinou M, et al. Detection of bladder cancer in urine sediments by a hypermethylation panel of selected tumor suppressor genes. Cancer Biomark. 2017;18(1):47\u201359.","journal-title":"Cancer Biomark"},{"issue":"1","key":"4096_CR70","volume":"2012","author":"F Fausti","year":"2012","unstructured":"Fausti F, Di Agostino S, Sacconi A, Strano S, Blandino G. Hippo and rassf1a pathways: a growing affair. Mol Biol Int. 2012;2012(1):307628.","journal-title":"Mol Biol Int"},{"issue":"10","key":"4096_CR71","doi-asserted-by":"publisher","DOI":"10.1098\/rsob.160119","volume":"6","author":"S-P Wang","year":"2016","unstructured":"Wang S-P, Wang L-H. Disease implication of hyper-Hippo signalling. Open Biol. 2016;6(10):160119.","journal-title":"Open Biol"},{"issue":"14","key":"4096_CR72","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1101\/gad.1664408","volume":"22","author":"B Zhao","year":"2008","unstructured":"Zhao B, Ye X, Yu J, Li L, Li W, Li S, et al. Tead mediates YAP-dependent gene induction and growth control. Genes Dev. 2008;22(14):1962\u201371.","journal-title":"Genes Dev"},{"key":"4096_CR73","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3389\/fcell.2019.00085","volume":"7","author":"K Snigdha","year":"2019","unstructured":"Snigdha K, Gangwani KS, Lapalikar GV, Singh A, Kango-Singh M. Hippo signaling in cancer: lessons from Drosophila models. Front cell Dev Biol. 2019;7:85.","journal-title":"Front cell Dev Biol"},{"key":"4096_CR74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-019-1421-7","volume":"38","author":"K Qiao","year":"2019","unstructured":"Qiao K, Ning S, Wan L, Wu H, Wang Q, Zhang X, et al. LINC00673 is activated by YY1 and promotes the proliferation of breast cancer cells via the miR-515-5p\/MARK4\/Hippo signaling pathway. J Exp Clin Cancer Res. 2019;38:1\u201315.","journal-title":"J Exp Clin Cancer Res"},{"key":"4096_CR75","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.canlet.2018.02.015","volume":"423","author":"T Lu","year":"2018","unstructured":"Lu T, Li Z, Yang Y, Ji W, Yu Y, Niu X, et al. The Hippo\/YAP1 pathway interacts with FGFR1 signaling to maintain stemness in lung cancer. Cancer Lett. 2018;423:36\u201346.","journal-title":"Cancer Lett"},{"issue":"8","key":"4096_CR76","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1158\/1078-0432.CCR-17-2986","volume":"24","author":"Q Wang","year":"2018","unstructured":"Wang Q, Gao X, Yu T, Yuan L, Dai J, Wang W, et al. REG\u03b3 controls Hippo signaling and reciprocal NF-\u03baB\u2013YAP regulation to promote colon cancer. Clin Cancer Res. 2018;24(8):2015\u201325.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"4096_CR77","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1515\/cclm-2020-0662","volume":"59","author":"E Karamitrousis","year":"2021","unstructured":"Karamitrousis E, Balgkouranidou I, Xenidis N, Amarantidis K, Biziota E, Koukaki T, et al. Association between SOX17, Wif-1 and RASSF1A promoter methylation status and response to chemotherapy in patients with metastatic gastric cancer. Clin Chem Lab Med (CCLM). 2021;59(2):e73\u20135.","journal-title":"Clin Chem Lab Med (CCLM)"},{"issue":"3","key":"4096_CR78","doi-asserted-by":"publisher","first-page":"313","DOI":"10.3233\/CBM-190258","volume":"27","author":"Q Deng","year":"2020","unstructured":"Deng Q, Su B, Ji X, Fang Q, Zhou S, Zhou C. Predictive value of unmethylated RASSF1A on disease progression in non-small cell lung cancer patients receiving pemetrexed-based chemotherapy. Cancer Biomark. 2020;27(3):313\u201323.","journal-title":"Cancer Biomark"},{"key":"4096_CR79","doi-asserted-by":"publisher","first-page":"5389","DOI":"10.12659\/MSM.903927","volume":"23","author":"X Sun","year":"2017","unstructured":"Sun X, Yuan W, Hao F, Zhuang W. Promoter methylation of RASSF1A indicates prognosis for patients with stage II and III colorectal cancer treated with oxaliplatin-based chemotherapy. Med Sci Monit. 2017;23:5389.","journal-title":"Med Sci Monit"},{"key":"4096_CR80","unstructured":"Camargo EAD, Silva GND, Gobette CP, Marcondes JPDC, Salvadori DMF (2013). No relationship between the amount of DNA damage and the level of hMLH1 and RASSF1A gene expression in bladder cancer cells treated with cisplatin and gemcitabine."},{"key":"4096_CR81","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s11010-019-03648-y","volume":"464","author":"M Khandelwal","year":"2020","unstructured":"Khandelwal M, Anand V, Appunni S, Seth A, Singh P, Mathur S, et al. RASSF1A\u2013Hippo pathway link in patients with urothelial carcinoma of bladder: plausible therapeutic target. Mol Cell Biochem. 2020;464:51\u201363.","journal-title":"Mol Cell Biochem"},{"key":"4096_CR82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-015-0120-2","volume":"34","author":"L Zhang","year":"2015","unstructured":"Zhang L, Xiong G, Fang D, Li X, Liu J, Ci W, et al. Contralateral upper tract urothelial carcinoma after nephroureterectomy: the predictive role of DNA methylation. J Exp Clin Cancer Res. 2015;34:1\u201311.","journal-title":"J Exp Clin Cancer Res"},{"issue":"5","key":"4096_CR83","doi-asserted-by":"publisher","first-page":"733","DOI":"10.2217\/epi.15.34","volume":"7","author":"G Xiong","year":"2015","unstructured":"Xiong G, Liu J, Tang Q, Fan Y, Fang D, Yang K, et al. Prognostic and predictive value of epigenetic biomarkers and clinical factors in upper tract urothelial carcinoma. Epigenomics. 2015;7(5):733\u201344.","journal-title":"Epigenomics"},{"key":"4096_CR84","volume-title":"Urologic oncology: seminars and original investigations","author":"R-Q Guo","year":"2018","unstructured":"Guo R-Q, Xiong G-Y, Yang K-W, Zhang L, He S-M, Gong Y-Q, et al. Detection of urothelial carcinoma, upper tract urothelial carcinoma, bladder carcinoma, and urothelial carcinoma with gross hematuria using selected urine-DNA methylation biomarkers: a prospective, single-center study. In: Urologic oncology: seminars and original investigations. Elsevier; 2018."},{"issue":"1","key":"4096_CR85","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.clgc.2022.10.008","volume":"21","author":"Y Lin","year":"2023","unstructured":"Lin Y, Lin L, Yang Y, Li M, Jiang X, Fu T, et al. DNA methylation architecture provides insight into the pathogenesis of upper tract urothelial carcinoma: a systematic review and meta-analysis. Clin Genitourin Cancer. 2023;21(1):32\u201342.","journal-title":"Clin Genitourin Cancer"},{"key":"4096_CR86","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S183142","author":"Q Zhuang","year":"2018","unstructured":"Zhuang Q, Chen Z, Shen J, Fan M, Xue D, Lu H, et al. RASSF1A promoter methylation correlates development, progression, and poor cancer-specific survival of renal cell carcinoma: trial sequential analysis. OncoTargets Ther. 2018. https:\/\/doi.org\/10.2147\/OTT.S183142.","journal-title":"OncoTargets Ther"},{"key":"4096_CR87","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev","author":"I Ure","year":"2019","unstructured":"Ure I, Konac E, Alp E, Onen H, Batur A, Gonul I, et al. Transcriptomic expression levels of the VHL, TIMP-3, and RASSF1A genes in renal tumors. Eur Rev Med Pharmacol Sci. 2019. https:\/\/doi.org\/10.26355\/eurrev.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"1","key":"4096_CR88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12894-018-0334-7","volume":"18","author":"D Fang","year":"2018","unstructured":"Fang D, He S, Xiong G, Singla N, Cao Z, Zhang L, et al. Comparison of clinicopathologic characteristics, epigenetic biomarkers and prognosis between renal pelvic and ureteral tumors in upper tract urothelial carcinoma. BMC Urol. 2018;18(1):1\u201317.","journal-title":"BMC Urol"},{"issue":"9","key":"4096_CR89","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.2217\/epi-2017-0040","volume":"9","author":"SC Joosten","year":"2017","unstructured":"Joosten SC, Deckers IA, Aarts MJ, Hoeben A, van Roermund JG, Smits KM, et al. Prognostic DNA methylation markers for renal cell carcinoma: a systematic review. Epigenomics. 2017;9(9):1243\u201357.","journal-title":"Epigenomics"},{"key":"4096_CR90","first-page":"1563","volume":"62","author":"R Minciu","year":"2016","unstructured":"Minciu R, Tudor A, Pupca G, Daminescu L, Dumache R. Renal cancer diagnosed by noninvasive methods from body fluids by quantitative methylation-specific PCR (qMSP). Clin Lab. 2016;62:1563\u20138.","journal-title":"Clin Lab"},{"issue":"12","key":"4096_CR91","doi-asserted-by":"publisher","first-page":"19712","DOI":"10.18632\/oncotarget.14966","volume":"8","author":"Y Liu","year":"2017","unstructured":"Liu Y, Sun L, Fong P, Yang J, Zhang Z, Yin S, et al. An association between overexpression of DNA methyltransferase 3B4 and clear cell renal cell carcinoma. Oncotarget. 2017;8(12):19712.","journal-title":"Oncotarget"},{"issue":"2","key":"4096_CR92","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.30058","volume":"70","author":"H Ueno-Yokohata","year":"2023","unstructured":"Ueno-Yokohata H, Okita H, Nakasato K, Kiyokawa N. Hypermethylation of RASSF1A gene in pediatric rhabdoid tumor of the kidney and clear cell sarcoma of the kidney. Pediatr Blood Cancer. 2023;70(2):e30058.","journal-title":"Pediatr Blood Cancer"},{"issue":"51","key":"4096_CR93","doi-asserted-by":"publisher","first-page":"7573","DOI":"10.1038\/sj.onc.1204968","volume":"20","author":"D Astuti","year":"2001","unstructured":"Astuti D, Agathanggelou A, Honorio S, Dallol A, Martinsson T, Kogner P, et al. RASSF1A promoter region CpG island hypermethylation in phaeochromocytomas and neuroblastoma tumours. Oncogene. 2001;20(51):7573\u20137.","journal-title":"Oncogene"},{"issue":"1","key":"4096_CR94","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1677\/ERC-06-0031","volume":"14","author":"J Geli","year":"2007","unstructured":"Geli J, Kiss N, Lanner F, Foukakis T, Natalishvili N, Larsson O, et al. The Ras effectors NORE1A and RASSF1A are frequently inactivated in pheochromocytoma and abdominal paraganglioma. Endocr Relat Cancer. 2007;14(1):125\u201334.","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"4096_CR95","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1476-4598-12-87","volume":"12","author":"R Korah","year":"2013","unstructured":"Korah R, Healy JM, Kunstman JW, Fonseca AL, Ameri AH, Prasad ML, et al. Epigenetic silencing of RASSF1A deregulates cytoskeleton and promotes malignant behavior of adrenocortical carcinoma. Mol Cancer. 2013;12(1):1\u201313.","journal-title":"Mol Cancer"},{"key":"4096_CR96","volume-title":"StatPearls [Internet]","author":"P Gurung","year":"2022","unstructured":"Gurung P, Yetiskul E, Jialal I. Physiology, male reproductive system. In: StatPearls [Internet]. Statpearls publishing; 2022."},{"issue":"9b","key":"4096_CR97","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1111\/j.1464-410X.2009.08854.x","volume":"104","author":"RP Manecksha","year":"2009","unstructured":"Manecksha RP, Fitzpatrick JM. Epidemiology of testicular cancer. BJU Int. 2009;104(9b):1329\u201333.","journal-title":"BJU Int"},{"issue":"1","key":"4096_CR98","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.juro.2009.02.106","volume":"182","author":"J Ellinger","year":"2009","unstructured":"Ellinger J, Albers P, Perabo FG, M\u00fcller SC, von Ruecker A, Bastian PJ. Cpg island hypermethylation of cell-free circulating serum DNA in patients with testicular cancer. J Urol. 2009;182(1):324\u20139.","journal-title":"J Urol"},{"issue":"12","key":"4096_CR99","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.2217\/epi-2018-0034","volume":"10","author":"AL Costa","year":"2018","unstructured":"Costa AL, Moreira-Barbosa C, Lobo J, Vilela-Salgueiro B, Cantante M, Guimaraes R, et al. DNA methylation profiling as a tool for testicular germ cell tumors subtyping. Epigenomics. 2018;10(12):1511\u201323.","journal-title":"Epigenomics"},{"issue":"5","key":"4096_CR100","first-page":"363","volume":"14","author":"D Markulin","year":"2017","unstructured":"Markulin D, Vojta A, Samar\u017eija I, Gamulin M, Be\u010deheli I, Juki\u0107 I, et al. Association between RASSF1A promoter methylation and testicular germ cell tumor: a meta-analysis and a cohort study. Cancer Genomics Proteomics. 2017;14(5):363\u201372.","journal-title":"Cancer Genomics Proteomics"},{"key":"4096_CR101","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.cancergen.2019.10.002","volume":"241","author":"F Ahmad","year":"2020","unstructured":"Ahmad F, Surve P, Natarajan S, Patil A, Pol S, Patole K, et al. Aberrant epigenetic inactivation of RASSF1A and MGMT gene and genetic mutations of KRAS, cKIT and BRAF in Indian testicular germ cell tumours. Cancer Genet. 2020;241:42\u201350.","journal-title":"Cancer Genet"},{"issue":"20","key":"4096_CR102","doi-asserted-by":"publisher","first-page":"5228","DOI":"10.3390\/cancers13205228","volume":"13","author":"J Lobo","year":"2021","unstructured":"Lobo J, van Zogchel LM, Nuru MG, Gillis AJ, van der Schoot CE, Tytgat GA, et al. Combining hypermethylated RASSF1A detection using ddPCR with miR-371a-3p testing: an improved panel of liquid biopsy biomarkers for testicular germ cell tumor patients. Cancers. 2021;13(20):5228.","journal-title":"Cancers"},{"issue":"4","key":"4096_CR103","doi-asserted-by":"publisher","first-page":"780","DOI":"10.3390\/cancers13040780","volume":"13","author":"M Zavridou","year":"2021","unstructured":"Zavridou M, Strati A, Bournakis E, Smilkou S, Tserpeli V, Lianidou E. Prognostic significance of gene expression and DNA methylation markers in circulating tumor cells and paired plasma derived exosomes in metastatic castration resistant prostate cancer. Cancers. 2021;13(4):780.","journal-title":"Cancers"},{"key":"4096_CR104","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13148-019-0779-x","volume":"11","author":"V Const\u00e2ncio","year":"2019","unstructured":"Const\u00e2ncio V, Nunes SP, Moreira-Barbosa C, Freitas R, Oliveira J, Pousa I, et al. Early detection of the major male cancer types in blood-based liquid biopsies using a DNA methylation panel. Clin Epigenetics. 2019;11:1\u201318.","journal-title":"Clin Epigenetics"},{"issue":"4","key":"4096_CR105","doi-asserted-by":"publisher","first-page":"e867","DOI":"10.1016\/j.clgc.2018.02.004","volume":"16","author":"BE S\u00e1nchez","year":"2018","unstructured":"S\u00e1nchez BE, Aguayo A, Mart\u00ednez B, Rodr\u00edguez F, Marmolejo M, Svyryd Y, et al. Using genetic and epigenetic markers to improve differential diagnosis of prostate cancer and benign prostatic hyperplasia by noninvasive methods in Mexican patients. Clin Genitourin Cancer. 2018;16(4):e867\u201377.","journal-title":"Clin Genitourin Cancer"},{"issue":"9","key":"4096_CR106","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0075283","volume":"8","author":"J Pan","year":"2013","unstructured":"Pan J, Chen J, Zhang B, Chen X, Huang B, Zhuang J, et al. Association between RASSF1A promoter methylation and prostate cancer: a systematic review and meta-analysis. PLoS ONE. 2013;8(9):e75283.","journal-title":"PLoS ONE"},{"issue":"7","key":"4096_CR107","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.3390\/cancers16071324","volume":"16","author":"M Friedemann","year":"2024","unstructured":"Friedemann M, Jandeck C, Tautz L, Gutewort K, von Rein L, Sukocheva O, et al. Blood-based DNA methylation analysis by multiplexed OBBPA-ddPCR to verify indications for prostate biopsies in suspected prostate cancer patients. Cancers. 2024;16(7):1324.","journal-title":"Cancers"},{"key":"4096_CR108","doi-asserted-by":"publisher","first-page":"1338468","DOI":"10.3389\/fgene.2024.1338468","volume":"15","author":"T Ding","year":"2024","unstructured":"Ding T, Diao Y, Zeng X, Zhou L, Wu G, Liu J, et al. Influential factors on urine EV DNA methylation detection and its diagnostic potential in prostate cancer. Front Genet. 2024;15:1338468.","journal-title":"Front Genet"},{"issue":"2","key":"4096_CR109","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1097\/MOU.0000000000000581","volume":"29","author":"A Douglawi","year":"2019","unstructured":"Douglawi A, Masterson TA. Penile cancer epidemiology and risk factors: a contemporary review. Curr Opin Urol. 2019;29(2):145\u20139.","journal-title":"Curr Opin Urol"},{"issue":"6","key":"4096_CR110","first-page":"481","volume":"66","author":"PE Spiess","year":"2016","unstructured":"Spiess PE, Dhillon J, Baumgarten AS, Johnstone PA, Giuliano AR. Pathophysiological basis of human papillomavirus in penile cancer: key to prevention and delivery of more effective therapies. CA Cancer J Clin. 2016;66(6):481\u201395.","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"4096_CR111","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0062175","volume":"8","author":"H-F Gou","year":"2013","unstructured":"Gou H-F, Li X, Qiu M, Cheng K, Li L-H, Dong H, et al. Epidermal growth factor receptor (EGFR)-RAS signaling pathway in penile squamous cell carcinoma. PLoS ONE. 2013;8(4):e62175.","journal-title":"PLoS ONE"},{"key":"4096_CR112","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1100\/tsw.2011.24","volume":"11","author":"MF Calmon","year":"2011","unstructured":"Calmon MF, Tasso Mota M, Vassallo J, Rahal P. Penile carcinoma: risk factors and molecular alterations. Sci World J. 2011;11:269\u201382.","journal-title":"Sci World J"},{"issue":"8","key":"4096_CR113","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/j.1440-1827.2008.02259.x","volume":"58","author":"N Yanagawa","year":"2008","unstructured":"Yanagawa N, Osakabe M, Hayashi M, Tamura G, Motoyama T. Detection of HPV-DNA, p53 alterations, and methylation in penile squamous cell carcinoma in Japanese men. Pathol Int. 2008;58(8):477\u201382.","journal-title":"Pathol Int"},{"key":"4096_CR114","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s00428-008-0597-6","volume":"452","author":"N Yanagawa","year":"2008","unstructured":"Yanagawa N, Osakabe M, Hayashi M, Tamura G, Motoyama T. Frequent epigenetic silencing of the FHIT gene in penile squamous cell carcinomas. Virchows Arch. 2008;452:377\u201382.","journal-title":"Virchows Arch"},{"issue":"6","key":"4096_CR115","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1111\/j.1464-410X.2008.07603.x","volume":"102","author":"D Guerrero","year":"2008","unstructured":"Guerrero D, Guarch R, Ojer A, Casas JM, Ropero S, Mancha A, et al. Hypermethylation of the thrombospondin-1 gene is associated with poor prognosis in penile squamous cell carcinoma. BJU Int. 2008;102(6):747\u201355.","journal-title":"BJU Int"},{"key":"4096_CR116","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.119504","volume":"277","author":"MJ Ramaiah","year":"2021","unstructured":"Ramaiah MJ, Tangutur AD, Manyam RR. Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy. Life Sci. 2021;277:119504.","journal-title":"Life Sci"},{"key":"4096_CR117","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2023.100938","volume":"68","author":"F Li","year":"2023","unstructured":"Li F, Zheng Z, Chen W, Li D, Zhang H, Zhu Y, et al. Regulation of cisplatin resistance in bladder cancer by epigenetic mechanisms. Drug Resist Updat. 2023;68:100938.","journal-title":"Drug Resist Updat"},{"issue":"18","key":"4096_CR118","first-page":"6688","volume":"61","author":"M-G Lee","year":"2001","unstructured":"Lee M-G, Kim H-Y, Byun D-S, Lee S-J, Lee C-H, Kim JI, et al. Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma. Can Res. 2001;61(18):6688\u201392.","journal-title":"Can Res"},{"issue":"8","key":"4096_CR119","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.3390\/cells9081850","volume":"9","author":"SP Nunes","year":"2020","unstructured":"Nunes SP, Henrique R, Jer\u00f3nimo C, Paramio JM. DNA methylation as a therapeutic target for bladder cancer. Cells. 2020;9(8):1850.","journal-title":"Cells"},{"issue":"3","key":"4096_CR120","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3390\/biom6030037","volume":"6","author":"E Xylinas","year":"2016","unstructured":"Xylinas E, Hassler MR, Zhuang D, Krzywinski M, Erdem Z, Robinson BD, et al. An epigenomic approach to improving response to neoadjuvant cisplatin chemotherapy in bladder cancer. Biomolecules. 2016;6(3):37.","journal-title":"Biomolecules"},{"issue":"16","key":"4096_CR121","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1002\/pros.22716","volume":"73","author":"N Damaschke","year":"2013","unstructured":"Damaschke N, Yang B, Bhusari S, Svaren J, Jarrard D. Epigenetic susceptibility factors for prostate cancer with aging. Prostate. 2013;73(16):1721\u201330.","journal-title":"Prostate"},{"key":"4096_CR122","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.pharmthera.2018.02.006","volume":"188","author":"K Agrawal","year":"2018","unstructured":"Agrawal K, Das V, Vyas P, Hajd\u00fach M. Nucleosidic DNA demethylating epigenetic drugs\u2013a comprehensive review from discovery to clinic. Pharmacol Ther. 2018;188:45\u201379.","journal-title":"Pharmacol Ther"},{"key":"4096_CR123","first-page":"341","volume":"5","author":"K Jones","year":"2021","unstructured":"Jones K, Zhang Y, Kong Y, Farah E, Wang R, Li C, et al. Epigenetics in prostate cancer treatment. J Trans Genet Genomics. 2021;5:341.","journal-title":"J Trans Genet Genomics"},{"key":"4096_CR124","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S251297","author":"M Mohammadi","year":"2020","unstructured":"Mohammadi M, Irani S, Salahshourifar I, Hosseini J, Moradi A, Pouresmaeili F. The effect of hormone therapy on the expression of prostate cancer and multi-epigenetic marker genes in a population of Iranian patients. Cancer Manag Res. 2020. https:\/\/doi.org\/10.2147\/CMAR.S251297.","journal-title":"Cancer Manag Res"},{"issue":"10","key":"4096_CR125","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1158\/1541-7786.MCR-20-0974","volume":"19","author":"W Liu","year":"2021","unstructured":"Liu W, Xie A, Tu C, Liu W. REX-1 represses RASSF1a and activates the MEK\/ERK pathway to promote tumorigenesis in prostate cancer. Mol Cancer Res. 2021;19(10):1666\u201375.","journal-title":"Mol Cancer Res"},{"issue":"7","key":"4096_CR126","doi-asserted-by":"publisher","DOI":"10.1002\/jgm.3498","volume":"25","author":"W Liu","year":"2023","unstructured":"Liu W, Xie A, Xiong J, Li S, Yang L, Liu W. WDR3 promotes stem cell-like properties in prostate cancer by inhibiting USF2-mediated transcription of RASSF1A. J Gene Med. 2023;25(7):e3498.","journal-title":"J Gene Med"},{"issue":"4","key":"4096_CR127","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1002\/em.22363","volume":"61","author":"TM Barros","year":"2020","unstructured":"Barros TM, Lima AP, Almeida TC, da Silva GN. Inhibition of urinary bladder cancer cell proliferation by silibinin. Environ Mol Mutagen. 2020;61(4):445\u201355.","journal-title":"Environ Mol Mutagen"},{"issue":"5","key":"4096_CR128","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.2741\/1970","volume":"11","author":"L Ma","year":"2006","unstructured":"Ma L, Feugang JM, Konarski P, Wang J, Lu J, Fu S, et al. Growth inhibitory effects of quercetin on bladder cancer cell. Front Biosci. 2006;11(5):2275\u201385.","journal-title":"Front Biosci"},{"key":"4096_CR129","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.phrs.2016.10.021","volume":"114","author":"SS Boyanapalli","year":"2016","unstructured":"Boyanapalli SS, Li W, Fuentes F, Guo Y, Ramirez CN, Gonzalez X-P, et al. Epigenetic reactivation of RASSF1A by phenethyl isothiocyanate (PEITC) and promotion of apoptosis in LNCaP cells. Pharmacol Res. 2016;114:175\u201384.","journal-title":"Pharmacol Res"},{"key":"4096_CR130","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1476-4598-12-99","volume":"12","author":"S Agarwal","year":"2013","unstructured":"Agarwal S, Amin KS, Jagadeesh S, Baishay G, Rao PG, Barua NC, et al. Mahanine restores RASSF1A expression by down-regulating DNMT1 and DNMT3B in prostate cancer cells. Mol Cancer. 2013;12:1\u201312.","journal-title":"Mol Cancer"},{"issue":"2","key":"4096_CR131","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/j.1365-2605.2010.01063.x","volume":"34","author":"R Lambrot","year":"2011","unstructured":"Lambrot R, Kimmins S. Histone methylation is a critical regulator of the abnormal expression of POU5F1 and RASSF1A in testis cancer cell lines. Int J Androl. 2011;34(2):110\u201323.","journal-title":"Int J Androl"},{"issue":"24","key":"4096_CR132","doi-asserted-by":"publisher","first-page":"9360","DOI":"10.1158\/0008-5472.CAN-09-1490","volume":"69","author":"MJ Beyrouthy","year":"2009","unstructured":"Beyrouthy MJ, Garner KM, Hever MP, Freemantle SJ, Eastman A, Dmitrovsky E, et al. High DNA methyltransferase 3B expression mediates 5-aza-deoxycytidine hypersensitivity in testicular germ cell tumors. Cancer Res. 2009;69(24):9360\u20136.","journal-title":"Cancer Res"},{"key":"4096_CR133","doi-asserted-by":"publisher","DOI":"10.2147\/BTT.S166310","author":"E Cruz","year":"2019","unstructured":"Cruz E, Kayser V. Monoclonal antibody therapy of solid tumors: clinical limitations and novel strategies to enhance treatment efficacy. Biologics Targets Ther. 2019. https:\/\/doi.org\/10.2147\/BTT.S166310.","journal-title":"Biologics Targets Ther"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04096-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-025-04096-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04096-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T05:02:34Z","timestamp":1774414954000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-025-04096-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":133,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["4096"],"URL":"https:\/\/doi.org\/10.1007\/s12094-025-04096-5","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,27]]},"assertion":[{"value":"28 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors report no real or perceived vested interests that relate to this article that could be construed as a conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable since this is a review paper without human subjects.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participation"}}]}}